E-mail Article

MDLinx E-mail Article

To email this article, enter your own "From Email" address, the recipient's "To Email" address, and click the "Send Email" button. You may send to up to 5 emails at a time.

* From Email:

* To Email:

To Email:

Email Subject Line:

Comments:

Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study

Barnes N et al.– During 1 year after initiating or stepping up ICS therapy by pressurized metered–dose inhaler (pMDI), patients who received extrafine–particle formulation of hydrofluoroalkane–beclometasone (EF HFA–BDP) were more likely to achieve asthma control than those receiving chlorofluorocarbon (CFC)–BDP. These findings suggest that inhaled corticosteroid (ICS) formulation, particle size, and deposition characteristics play important roles in real–life effectiveness of asthma therapy. This study shows that an EF–particle formulation of beclometasone can be used at half the dose of the large–particle formulation with at least as good clinical outcomes. [more...]

Clinical & Experimental Allergy

Stay current on the latest literature, research and clinical news
Get special communications and offers from MDLinx and our sponsors
Receive invitations to paid market research

View Samples and Register

Stay current - Media Tool

Newsletter

RSS

Facebook

Receive free subspecialty
"5-minute updates" via email

Send the E-mail Newsletter to a Colleague

♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦

♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦

♦ Follow Us on Facebook

Search the latest
Allergy/Immunology Jobs
@MDLinx Career Center
View the full listing of physician jobs

Enter your email address and your password will be sent to you.
Email:

E-mail:
Password:
	Remember me Forgot your password?